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REVIEW ARTICLE
The Results of Spinal Cord Stimulation in Critical Limb Ischaemia:
a Review
G. H. J. J. Spincemaille∗1, H. C. W. de Vet2, D. Th. Ubbink3 and M. J. H. M. Jacobs3
1Department of Neurosurgery, Academic Hospital Maastricht, 2Department of Epidemiology, University Maastricht,
and 3Department of Vascular Surgery, Academic Medical Centre, Amsterdam, The Netherlands
Objectives: to determine which patients with unreconstructible critical limb ischaemia (CLI) might benefit from spinal
cord stimulation (SCS).
Methods: literature review.
Results: limb salvage in patients with an intermediate transcutaneous oxygen pressure (TcpO2) was not significantly
higher with SCS (76%) than with conservative therapy (p=0.08). However, a limb salvage of 88% was achieved with
SCS if the difference between the supine and sitting TcpO2 baseline values (TcpO2) was [15 mmHg. A rise in TcpO2
after trial stimulation of at least 15% resulted in a limb salvage of 77% at 18 months (p<0.01).
Conclusion: randomised studies show no benefit of SCS over conservative therapy in patients with non-reconstructible
CLI. However, data from experimental and non-randomised studies suggest this may be due to sub-optimal patient
selection for SCS. Further trials are needed to identify subgroups who may benefit from SCS.
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Introduction Methods
Reference material was obtained from Medline (1980–Patients with non-reconstructible critical limb isch-
2000), the Cochrane database, congress proceedingsaemia (CLI) have a poor prognosis.1 Cook was the
(INS, Groningen, Orlando, Luzern) and books. In-first to suggest that spinal cord stimulation (SCS) might
clusion criteria were (i) unreconstructible CLI, (ii) mini-avert the need for amputation in a proportion of such
mum 20 patients, (iii) minimum 6 months’ follow-up,patients.2 Dooley also believed that SCS would increase
(iv) assessment of the micro- and macrocirculation inblood flow to the limb and reduce pain.3 Non-ran-
relation to limb salvage (Table 1).domised studies suggested that SCS might increase
limb salvage by 40–50%.4–8 However, this has not
Resultsbeen borne out by randomised controlled trials (RCTs)
which, in general, showed treatment such as prosta- Many reports did not fulfil the inclusion criteria.15–23
glandins and SCS to be only 10–20% better than stand- Studies which did meet the criteria are shown in Table
ard conservative therapy.9–12 1 and, unsurprisingly, comprised high-risk patients
Experimental data suggest that SCS may have a with some pain and/or tissue loss (Table 2). The mean
beneficial effect upon the microcirculation of certain limb salvage after SCS in the studies was 62% (range
patients13 and that TcpO2 might be able to distinguish 60% to 68%), with a follow-up of 2 years (Fig. 1).
responders from non-responders.5,6,9,13,14 Mortality was very high: about 33% after a follow-up
The aim of the review was to identify which patients of 2 years and 50% after 5 years (Table 3).
with non-reconstructible CLI might benefit from SCS.
Microcirculatory data
∗ Please address all correspondence to: G. H. J. J. Spincemaille,
Department of Neurosurgery, University Hospital AZM, P. De- The results are summarised in Tables 4 and 5. Galley
et al.5 found a significant increase in TcpO2 (13.5 tobyelaan 25, 6202 AZ Maastricht (NL).
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Table 1. List of selected articles.
Author Year n n (PAOD) n (PAOD) Follow-up: Selection Level of
SCS controls months criteria evidence
treatment (mean)
Augustinsson 1985 44 27 10 16 1,2 2
Galley 1992 244 208 0 24 1,2,3 1
Horsch 1994 177 177 0 35.6 1
Jivegard 1995 51 25 26 18 1,2 3
Claeys 1996 86 45 41 12 1,2,3 3
Gersbach 1997 20 20 0 14 1,2,3 1
Kumar 1997 46 46 0 21 1,2,3 1
Klomp, Ubbink 1999 120 60 60 20 1,2,4 3
Total 788 608 137
n=all patients including other diseases than PAOD.
n (PAOD)=only patients with peripheral arterial occlusive disease.
Selection criteria: 1=macrocirculatory data; 2=microcirculatory data; 3=trial stimulation and TcpO2 evaluation; 4=capillary microscopy.
Level of evidence: 1=case reports; 2=cohort studies with historical controls; 3=randomised studies.
for 1 week irrespective of the initial microcirculatory
data. Baseline supine TcpO2 was 19.5±15 mmHg and
baseline-sitting TcpO2 was 42±15 mmHg (TcpO2=
23 mmHg). Retrospective analysis of the different tests
revealed that the supine-sitting TcpO2 gradient was
the strongest predictor of limb salvage. If the gradient
was greater than 15 mmHg, limb salvage rate (LSR)
was as high as 88%. All patients with a sitting TcpO2
Ζ20 mmHg underwent amputation of the ischaemic
limb.
Kumar et al.24 treated patients only if they had
undergone a 6-month period of conservative therapy
for pain relief. Patients with excellent pain relief (>75%)
and a substantial increase in TcpO2 after trial stimu-
lation showed a significant positive correlation with
long-term success. Patients with a TcpO2 of less than
10 mmHg following stimulation tended to undergo an
amputation within the first 3 months. Improvement
in pain control combined with an increase in TcpO2
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Fig. 1. Limb survival in patients with critical limb ischaemia. Data dictors of long-term success. The best results were
of the Dutch randomised trial. seen in patients with severe claudication and rest pain
without trophic changes in the foot.
Claeys et al.9 compared SCS with optimal medical24 mmHg, p<0.001) following 9±4 days of SCS. The
treatment (OMT). Patients started with 1 week ofTcpO2 (sitting) changed from 24.4±22 (before stimu-
prostaglandin treatment (PGE1), after which they werelation) to 50.4±18 (after stimulation). The gradient
randomised between SCS+PGE1 and PGE1 alone. Ini-between sitting and supine TcpO2 (TcpO2) increased
tial mean value of TcpO2 was 10 mmHg (SCS) vsfrom 22.4±22 (prestimulation) to 41.4±18 (post-
11 mmHg. At 12 months TcpO2 was 21 mmHg vs 11.4,stimulation).
respectively (p<0.0001). The outcome of patients withHorsch et al.7 reported on 177 patients belonging to
an initial TcpO2Ζ10 mmHg was significantly less thanthe Fontaine stages III (n=114) and IV (n=63). A
those with a TcpO2 >10 mmHg.SCS system was implanted in 139 patients who had
Ubbink et al. categorised patients according the sta-excellent pain relief after stimulation. Mean supine
tus of their baseline skin microcirculation in goodTcpO2 was 24 mmHg in stage III and 16 mmHg in
(TcpO2 above 30 mmHg), intermediate (TcpO2 betweenstage IV patients. During treatment TcpO2 increased
10 and 30 mmHg) and poor (TcpO2 below 10 mmHg).to 48 and 37 mmHg, respectively.
Gersbach et al.6 started with a trial period of SCS Patients with a poor skin perfusion had a high am-
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Table 2. Characteristics of patients with critical ischaemia from Pain reduction
Klomp.11
Characteristic % Pain reduction after trial stimulation was repeatedly
suggested to correlate with limb salvage.7,24 In the
Female 45 Dutch randomised study a trial stimulation was notAge (mean) 73
Diabetes 37 performed. A retrospective analysis looked at the limb
Contralateral leg – symptomatic 32 salvage at 6 months and 1-year follow-up of patients,
amputated 15 which had a good or excellent pain relief scored at 1-Smoking – not for >1 year 37
still smoking 30 month follow-up. The results between both treatment
CVA/TIA 22 groups were comparable, proving that pain relief on
Myocardial infarction 38 itself was important, but not the way it was obtained.Angina pectoris 20
Ulcerations/gangrene 63 Patients with a bad response on pain had significantly
Gangrene – dry 40 lower limb salvage in both treatment groups, in-
wet 13 dicating that pain relief was related to limb salvage.Previous vascular surgery – none 25
1 or 2 42 One of the effects of pain relief is certainly the enhanced
>3 32 mobility of the patients, which may be responsible for
Sympathectomy (randomised leg) 35 a secondary amelioration in blood flow.11Ankle pressure (mean±SD in mmHg) 35.2±24.8
Ankle-brachial index (mean±SD) 0.23±0.16
TcpO2 at rest (mmHg) 10
TcpO2 peak (mmHg) 12
Algorithm design
Table 3. Literature data about limb salvage.
Based on this review, it is suggested that SCS is not
Case reports
indicated if patients have a baseline TcpO2 (supine
SCS and sitting) below 10 or above 30 mmHg9,25 or aTcpO2
below 15 mmHg.5,6 The eligible patients go on with a
Author n Limb Follow-
period of trial stimulation. At the end of that periodsurvival up
(years) pain relief and changes in TcpO2 are recorded. If
pain relief is below 50%, adjustment of medication is
Augustinsson 26 62% 1
allowed to enhance pain relief. Should pain relief beGalley 199 64% 2
Horsch 177 66% 4 above 50% and the change in TcpO2 be more than
Gersbach 20 63% 2 15 mmHg,5,24 full implantation is considered. If no
Kumar 46 65% 2
positive response is obtained, SCS is not indicated
and symptomatic treatment is given, consisting of
Randomised controlled trials analgesics, vasoactive drugs and adequate care of foot
ulcers.SCS Conservative
This paradigm requires validation within a RCT
Author n Limb Follow- n Limb (Fig. 2).
survival up survival
(years)
Jivegard 25 62% 112 26 45%
Claeys 45 68% 1 41 65%
DiscussionKlomp 60 60% 2 60 46%
Follow-up in the case studies and randomised controlled trials At present, the best available evidence indicates that
(RCT). Mortality in the RCT was between 22% and 33% at 1-year
selection of patients for SCS cannot be based on thefollow-up. Limb survival in years of follow-up. Conservative=
conservative treatment. European consensus document or on the Fontaine
grading. As skin microcirculation seems to be the
major target of SCS, it seemed logical to look moreputation rate of 80% for SCS and 71% for standard
treatment. Patients with a good microcirculation had carefully at TcpO2, laser Doppler and capillary micro-
scopy. The initial TcpO2 value as measured at rest ina good outcome irrespective of the treatment given.
Amputation in patients treated conservatively with the supine position appears to be a simple stand-alone
parameter that is closely related to limb survival. Otheran intermediate TcpO2 value was half of that in the
standard group (24 vs 48%).25 This categorisation had TcpO2 parameters involved in the selection of patients,
such as the difference between sitting and supinea predictive value regarding limb salvage.14
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Table 4. Microcirculatory data.
A. Case reports B. RCT’s
Baseline Follow-up Baseline Follow-up
TcpO2 at rest Change in TcpO2 TcpO2 at rest Change in TcpO2
(supine) (supine)
Galley¶5 13 + 77%∗∗ Claeys‡9
Horsch†7 16 +130%∗ SCS 10 +100–137%
Gersbach 19 +120%∗∗ Conserv. 11 None
Kumar 23 +130%∗ Ubbink§
10 +70%SCS
Conserv. 9 None
Comparison of baseline and follow up values of TcpO2 in non-randomised (A) and randomised studies (B). TcpO2 values presented in
mmHg. ∗=p<0.05. ∗∗=p<0.001. All data are mean values and mmHg. ¶ Only 77 out of 244 patients had TcpO2 measurements. The resting
TcpO2 is much lower than in other reports. † The better the end result (pain relief, ulcer healing), the higher was the increase in TcpO2.
The standard group receiving optimal medical treatment did not show any increase in TcpO2. ‡ Randomised study. Conservative treatment
included prostaglandins. § Results from the Dutch randomised trial.11 Increase in median TcpO2 for the SCS group. No change observed
in the standard group.
C. The supine-sitting TcpO2 gradient (TcpO2)
Baseline Prestim. Poststim.
TcpO2 (supine) TcpO2 (sitting) TcpO2 TcpO2
Galley¶5 13 24 22∗∗ 41
Gersbach6 19 42 23
TcpO2 values presented in mmHg. ∗=p<0.05. ∗∗=p<0.001. All data are mean values and
mmHg.
¶ The mean value of the sitting TcpO2 as mentioned in the article is lower than expected.
However, a difference (gradient) between supine and sitting is in the same range as the
data of Gersbach6. The effect after stimulation on the gradient is given only by Galley.
TcpO2, increase of TcpO2 after trial stimulation and diabetes,14,26 as well as in predicting wound healing in
diabetic feet.27pain reduction after stimulation, need more evaluation.
We suggest that CLI patients unsuitable for vascular A prospective study, which to some extent uses the
above mentioned algorithm approach, is underwayreconstruction who have a good or poor TcpO2 should
remain under surveillance. Patients with a TcpO2 be- (SCS-EPOS – Medtronic). It is, however, a non-ran-
domised study. This approach was considered in-tween 10 and 30 mmHg and a TcpO2 >15 mmHg are
considered for SCS. At this point randomisation is evitable, since refining the selection criteria results in
a splitting up of patient groups in categories too smallperformed. If a patient is selected for SCS, further
analysis is performed on pain relief and change in to be used for statistical analysis. For a country like
The Netherlands, with a population of 15 millionTcpO2 during the trial stimulation period. For both
treatments the primary outcome is limb survival. Sec- people, the target group of patients with CLI and
belonging to a specific group according to the TcpO2ondary outcomes are the analysis of pain relief and
the changes in TcpO2 during follow-up. (intermediate group as described by Ubbink) is prob-
ably not larger than 20–30 patients a year. It can beThe use of capillary microscopy and laser Doppler
may further increase discriminative power, but seems estimated from the power calculation of the study that
in order to detect a difference of 30% in limb survivalto be restricted to those departments which have vas-
cular surgery as a major topic and are devoted to those between treatments (50% vs 80% with SCS), with an
 level of 5%, less than 90 patients are needed for eachmeasurements, which requires a lot of expertise and
special equipment. Some other questions still remain treatment to prove a statistical difference.
In conclusion, there are different ways to betterto be clarified regarding the prognostic value of some
patient-related risk factors, like hypertension and dia- select patients who may potentially respond to a treat-
ment like SCS. Using one of them could result in anbetes.6,9,21 In the Dutch study no prognostic value of
the ankle pressure or diabetes was found. In contrast, increase of 10–20% in limb salvage compared to the
results found in randomised trials. A study to provemicrocirculatory parameters appear to have additional
value in detecting critical leg ischemia and predicting this hypothesis is feasible, as the number of patients
needed is between 60 and 90 for each treatment option.an imminent amputation, even in the presence of
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SCS
3.
2.
1.
2.
1.
∆ TcpO2 (sitting – supine)
TcpO2 supine
TcpO2 measurement
and
Non reconstructable –
critical limb ischaemia
Randomisation
Patients selected
for study
> 10 mm Hg
> 15 mm Hg
< 30 mm Hg
Patients excluded
but under
surveillance
< 10 mm Hg
< 15 mm Hg
> 30 mm Hg
Conservative treatment
In both groups pain relief and change in TcpO2 is
followed.
In the SCS group:
   effect of trial stimulation is evaluated
   subgroups
      (a) Pain relief < or > 50%
      (b) > or < than 15% change in TcpO2
Fig. 2. Algorithm for patient selection.
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Table 5. Comparison of limb survival with and without specific TcpO2 measurements.
A.
Author Categorisation TcpO2 Effect of stimulation in trial
period
Change in Pain relief
TcpO2
1 2 3 4
Galley
Gersbach >15 mmHg Increase of 15% Complete
of base value pain relief
Kumar Comparable to Substantial >75%
Ubbink
Claeys >10 mmHg
Ubbink Intermediate
(>10mm and
<30 mmHg)
(A) Description of the different methods used. Galley uses method 2–4 but gives no clear
definition for success. The other authors give criteria as described in the table.
B.
Author Limb Limb survival Method used
survival (%) expected using 1, 2,
3 or 4
Galley 62 ? 2–3–4
Gersbach 63 > 83 3–4
Gersbach 63 > 88 2
Kumar 65 > 77 1, 3–4
Claeys 68 ? 1
Ubbink 60 > 72 1
(B) Suggested gain in limb survival and the different methods used.
The authors indicated with (?) in the column – expected limb survival
– give suggestions and describe the different measures but do not
indicate the actual effect on limb survival.
Different methods are numbered 1–4. Limb survival in column 2 is the
survival according treatment following the European consensus. The
expected limb survival is given in column 3 and is the result of a more
accurate selection procedure using one of the methods mentioned.
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